List of Excipients in Branded Drug LEVOTHYROXINE SODIUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lannett Company Inc	LEVOTHYROXINE SODIUM	levothyroxine sodium	0527-3281	CELLULOSE, MICROCRYSTALLINE
Lannett Company Inc	LEVOTHYROXINE SODIUM	levothyroxine sodium	0527-3281	MAGNESIUM STEARATE
Lannett Company Inc	LEVOTHYROXINE SODIUM	levothyroxine sodium	0527-3281	SILICON DIOXIDE
Lannett Company Inc	LEVOTHYROXINE SODIUM	levothyroxine sodium	0527-3281	SODIUM STARCH GLYCOLATE TYPE A POTATO
Lannett Company Inc	LEVOTHYROXINE SODIUM	levothyroxine sodium	0527-4951	GELATIN
Lannett Company Inc	LEVOTHYROXINE SODIUM	levothyroxine sodium	0527-4951	GLYCERIN

Generic Drugs Containing LEVOTHYROXINE SODIUM

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	levothyroxine sodium	0378-1800	BUTYLATED HYDROXYANISOLE
Mylan Pharmaceuticals Inc	levothyroxine sodium	0378-1800	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	levothyroxine sodium	0378-1800	CROSPOVIDONE
Mylan Pharmaceuticals Inc	levothyroxine sodium	0378-1800	FD&C YELLOW NO. 6
Mylan Pharmaceuticals Inc	levothyroxine sodium	0378-1800	MAGNESIUM STEARATE
Mylan Pharmaceuticals Inc	levothyroxine sodium	0378-1800	MANNITOL

What are the Most Frequently-Used Excipients in LEVOTHYROXINE SODIUM?

# Of NDCs	Excipient
2	ACACIA
2	AKA218
2	ALPHA-TOCOPHEROL
1	AQUA
6	BLUE 1
21	BUTYLATED HYDROXYANISOLE

Last updated: August 10, 2026

Executive summary: Levothyroxine sodium is a mature, highly competitive drug with limited opportunity for new active-ingredient patents. Commercial value is concentrated in excipient-controlled differentiation: softgel and oral-solution delivery, lactose-free and sugar-free formulations, improved low-dose content uniformity, reduced food and drug interaction effects, pediatric usability, and supply reliability. The principal regulatory constraint is the narrow therapeutic index. Small changes in dissolution, absorption, potency, or manufacturing consistency can affect thyroid-stimulating hormone control, increasing the importance of formulation evidence and post-market quality monitoring.

Levothyroxine Sodium Excipient Strategy and Commercial Opportunities

What excipients are used in levothyroxine sodium products?

Levothyroxine sodium tablets use conventional solid-dose excipients, while softgel and oral-solution products rely on simpler excipient systems. The formulation choice affects stability, dissolution, patient tolerability, storage, manufacturing complexity, and differentiation.

Product or formulation type	Representative excipients	Commercial positioning
Conventional tablets	Calcium sulfate, microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, starches, sugars, talc, colorants	Low cost, broad generic competition
Synthroid tablets	Calcium sulfate, acacia, confectioner's sugar, povidone, talc, sodium starch glycolate, color additives depending on strength	Branded tablet with established physician recognition
Euthyrox tablets	Mannitol, cornstarch, citric acid, gelatin, magnesium stearate, colorants depending on strength	Tablet alternative with a distinct excipient profile
Tirosint softgels	Gelatin, glycerin, and water	Low-excipient, liquid-filled capsule platform
Tirosint-SOL oral solution	Glycerol and water	Single-dose liquid, low excipient burden
Compounded formulations	Varies by pharmacy and vehicle	Customized dosing, but greater quality and consistency concerns

Product-specific composition must be confirmed against the current FDA-approved labeling and DailyMed entry because excipients can vary by strength, manufacturer, market, and manufacturing site [1-5].

The most important excipient variables are:

1. Diluent and filler selection.
2. Binder and disintegrant performance.
3. Lubricant concentration.
4. Moisture sensitivity.
5. Capsule shell composition.
6. Solution vehicle and preservative strategy.
7. Colorants and allergen declarations.
8. Compatibility with low-dose levothyroxine loading.

Why does levothyroxine require a specialized excipient strategy?

Levothyroxine has a narrow therapeutic index and is administered in microgram quantities. Small changes in delivered dose or absorption can change thyroid-stimulating hormone levels. The formulation therefore must control both chemical potency and in vivo exposure.

Levothyroxine is also sensitive to food, minerals, gastric conditions, and concomitant medicines. Calcium and iron products can reduce absorption when taken together. Proton-pump inhibitors, antacids, bile-acid sequestrants, sucralfate, fiber, and selected gastrointestinal therapies can also affect exposure or administration timing [6].

An excipient strategy should address five technical risks:

Technical risk	Formulation implication
Very low active load	High blend uniformity and low-dose content control are essential
Narrow therapeutic index	Dissolution and bioequivalence changes require tight control
Moisture and chemical instability	Packaging, water activity, and manufacturing humidity require control
Food and gastric effects	Softgel or solution platforms can support differentiated absorption behavior
Patient switching between products	Consistent dose delivery and clear product identification are commercially important

Excipients do not eliminate levothyroxine's pharmacokinetic and pharmacodynamic variability. They can, however, reduce formulation-related variability and create a basis for regulatory and commercial differentiation.

What formulation patents protect levothyroxine sodium products?

The original levothyroxine sodium composition and basic tablet concepts are long out of patent protection. Commercially relevant protection is more likely to involve formulation architecture, manufacturing controls, delivery systems, packaging, or specific methods of use.

Softgel formulation patents

Softgel products can use gelatin-based shells and a liquid fill containing levothyroxine sodium, glycerin, and water. The formulation may be differentiated through:

• Reduced excipient count.
• Improved content uniformity.
• Liquid-fill manufacturing.
• Dissolution behavior.
• Reduced sensitivity to tablet disintegration.
• Use in patients who have difficulty absorbing or tolerating tablets.

The commercial value of these claims depends on claim scope, patent expiration, Orange Book listings, regulatory exclusivity, and whether a generic can design around the formulation.

Oral-solution formulation patents

Single-dose oral solutions can use glycerol and water or another aqueous vehicle. Relevant claim categories may include:

• Levothyroxine concentration ranges.
• Unit-dose packaging.
• Chemical stability.
• Container-closure systems.
• Dosing accuracy.
• Manufacturing and filling methods.
• Use in patients with swallowing or absorption challenges.

Oral-solution protection is more likely to support a 505(b)(2) product or branded reformulation than a conventional ANDA strategy, depending on the reference product and regulatory pathway.

Manufacturing and packaging claims

Manufacturing claims can address:

• Blend uniformity at microgram-scale drug loading.
• Low-shear mixing.
• Granulation or dry-blending conditions.
• Moisture control.
• Light protection.
• Unit-dose packaging.
• Stability through the labeled shelf life.

These claims can be commercially useful even when the active ingredient is old. Their strength depends on whether the manufacturing process is externally observable and whether an alternative process can produce an equivalent product.

What is the FDA regulatory status of levothyroxine sodium?

Levothyroxine sodium is FDA-approved for hypothyroidism, thyroid-stimulating hormone suppression in selected thyroid cancer settings, and other thyroid-related indications described in approved labeling. It is available in tablets, capsules, and oral-solution products [1-5].

The principal regulatory routes are:

Product strategy	Likely pathway	Main evidence burden
Conventional generic tablet	ANDA under section 505(j)	Pharmaceutical equivalence, bioequivalence, quality, stability
New softgel or oral solution	505(b)(2) or product-specific pathway	Clinical or comparative exposure evidence, formulation justification
New strength or dosing presentation	ANDA or 505(b)(2), depending on changes	Dose proportionality, bioequivalence, stability, labeling
Pediatric liquid	505(b)(2) or equivalent application	Dosing accuracy, palatability, stability, usability
Compounded preparation	Pharmacy compounding framework	State and federal compounding requirements; not equivalent to FDA approval

FDA has treated levothyroxine as a narrow therapeutic index product and has placed substantial emphasis on product-specific bioequivalence and interchangeability considerations. FDA's product-specific guidance and approval history should be reviewed before selecting an ANDA or 505(b)(2) strategy [7].

What is the Orange Book status of levothyroxine sodium?

The Orange Book identifies approved drug products, therapeutic equivalence evaluations, patents submitted for applicable products, and exclusivity information. Conventional levothyroxine tablets have long been subject to extensive generic competition and are generally evaluated through therapeutic-equivalence listings where the relevant FDA requirements are met [8].

Orange Book analysis should be conducted by:

• Active ingredient.
• Dosage form.
• Strength.
• Reference-listed drug.
• Patent or exclusivity listing.
• Product-specific approval pathway.

Softgel and oral-solution products can have a different Orange Book profile from tablets. A product may face fewer direct competitors if its dosage form, strength, or reference product is specialized. The absence of a listed patent does not eliminate formulation or regulatory barriers. It does mean that litigation-based protection may be weaker than market protection based on manufacturing complexity, brand loyalty, or clinical preference.

When does levothyroxine sodium lose exclusivity?

The active ingredient has already lost basic molecule-level exclusivity. Commercial exclusivity now depends on product-specific factors.

Exclusivity layer	Status for conventional levothyroxine
New chemical entity exclusivity	Expired
Basic composition-of-matter patent	Expired or commercially irrelevant
Tablet formulation protection	Mostly mature and heavily competed
Softgel formulation protection	Product-specific; requires current patent and Orange Book review
Oral-solution formulation protection	Product-specific; may support differentiated regulatory protection
Pediatric exclusivity	May apply only if granted for a qualifying product and indication
Orphan exclusivity	Generally not the central commercial protection for routine hypothyroidism products
Trademark and trade dress	Potentially relevant but weaker than patent protection
Manufacturing know-how	Can remain valuable without public patent protection

Patent expiration should be assessed at the individual product level. A statement that "levothyroxine patents have expired" is insufficient because it does not address softgel, oral-solution, unit-dose, or manufacturing claims.

Which companies compete in levothyroxine sodium?

The market includes branded innovators, generic manufacturers, specialty formulation companies, and compounding pharmacies.

Representative competitors include:

• AbbVie, through Synthroid.
• IBSA Pharma, through Tirosint and Tirosint-SOL in the United States.
• Merck KGaA and associated commercial entities, through Euthyrox in relevant markets.
• Lannett and other generic manufacturers, subject to product availability and ownership changes.
• Sandoz, Amneal, Hikma, and other generic suppliers, depending on the specific strength and market.
• Specialty pharmacies and outsourcing facilities for compounded products.

Market participation varies by strength. The 25 microgram, 50 microgram, 75 microgram, 100 microgram, 125 microgram, 150 microgram, 175 microgram, and 200 microgram strengths may have different competitive conditions. Low-volume strengths can present supply opportunities if competitors discontinue products or face manufacturing constraints.

What excipient opportunities exist in levothyroxine sodium?

Low-excipient formulations

Softgels and oral solutions can be positioned for patients who experience intolerance, inconsistent absorption, or difficulty using conventional tablets. A low-excipient product can also target patients avoiding lactose, gluten-containing ingredients, selected dyes, sugar, or complex tablet compositions.

The commercial claim must remain precise. "Fewer excipients" is easier to support than a broad claim of superior clinical performance. Any absorption or consistency claim requires comparative evidence.

Lactose-free and allergen-conscious tablets

Lactose-free, gluten-free, dye-free, and sugar-free tablets can address pharmacy substitution, dietary restrictions, and patient preference. This opportunity is more defensible when supported by:

• A clear inactive-ingredient profile.
• Consistent labeling across strengths.
• Reliable supply.
• A validated quality-control program.
• Physician and pharmacist education.

The market may not support a large premium for a conventional tablet solely because it is lactose-free. The opportunity improves when the product combines allergen-conscious excipients with better supply continuity or a differentiated dosing presentation.

Pediatric and geriatric delivery

Oral solutions and softgels can improve administration for:

• Infants and young children.
• Older adults with dysphagia.
• Patients receiving enteral nutrition.
• Patients requiring dose titration.
• Caregivers who need precise unit-dose administration.

Pediatric products require careful control of dose accuracy, palatability, container usability, microbial quality, and storage. A multidose bottle may lower cost but introduce dosing and stability risks. Unit-dose packaging increases manufacturing and packaging costs but can improve dosing precision and adherence.

Reduced interaction and absorption variability

The strongest commercial opportunity is a formulation that demonstrates clinically meaningful consistency under conditions where tablets can be difficult to manage. This could include patients with gastrointestinal disorders, altered gastric acidity, or complex medication schedules.

Such positioning requires controlled clinical or pharmacokinetic evidence. Excipients alone do not establish reduced interaction risk. The product must demonstrate an advantage through comparative studies, labeling, or real-world evidence.

Unit-dose and adherence packaging

Unit-dose oral solution or blister packaging can support:

• Hospital use.
• Nursing-home administration.
• Pediatric dosing.
• Travel and portability.
• Separation from calcium, iron, and other interacting medicines.

Packaging can be protected through device, container-closure, or method claims. It can also create practical differentiation where tablet chemistry is difficult to patent.

How strong is the patent estate for levothyroxine sodium?

The overall estate is weak at the active-ingredient level and potentially stronger at the product level.

Patent category	Relative strength	Reason
Active ingredient	Very low	Long-established generic drug
Conventional tablet composition	Low	Numerous design-around options
Softgel delivery system	Moderate	Manufacturing and formulation complexity can limit copying
Oral solution	Moderate	Stability, concentration, packaging, and dosing claims may be relevant
Manufacturing process	Variable	Stronger if process parameters are difficult to detect or reproduce
Container-closure system	Variable	Commercially useful but often narrow
Method of use	Low to moderate	Many therapeutic uses are established; narrow patient subsets may be more defensible
Trade secrets	Moderate	Blend, fill, stability, and process controls can remain valuable

Patent strength should be scored by claim breadth, remaining term, enforceability, detectability of infringement, design-around cost, and dependence on regulatory approval. A narrow formulation patent may have high commercial value if the product has strong physician adoption and limited substitutes, even when the patent estate is not broad.

Are Paragraph IV challenges likely for levothyroxine sodium?

Paragraph IV challenges are most relevant to branded softgel and oral-solution products with listed patents. Conventional tablet products are more exposed to routine ANDA competition because the active ingredient and tablet technology are mature.

A generic challenger may pursue one of four approaches:

1. Argue that a listed patent is invalid.
2. Argue that the patent is not infringed.
3. Develop a formulation outside the patent claims.
4. Target a different dosage form or reference product.

The risk is highest when the branded product has meaningful sales, multiple available strengths, a clear ANDA pathway, and patent claims that do not require difficult clinical differentiation. The risk is lower when approval requires a 505(b)(2) strategy, the dosage form is technically complex, or the product has a narrow patient base.

What patent litigation and settlement issues affect levothyroxine?

Litigation exposure is product-specific rather than molecule-wide. Relevant disputes may involve:

• Softgel capsule formulation claims.
• Oral-solution stability claims.
• Infringement by a generic or reformulated product.
• Patent-term calculation.
• Certification under the Hatch-Waxman framework.
• Launch timing after settlement.
• Authorized-generic arrangements.
• Manufacturing-site or supplier changes.

Settlement agreements can delay generic entry, permit an authorized generic, establish a licensed launch date, or allocate particular strengths to different market participants. A commercial diligence review should compare the FDA approval date, Orange Book patent listings, litigation docket, settlement terms, and actual market launch.

What manufacturing and IP barriers limit new entrants?

Levothyroxine manufacturing is deceptively difficult because the active dose is small and the therapeutic window is narrow.

Key barriers include:

• Accurate microgram-scale dispensing.
• Homogeneous distribution of active ingredient.
• Control of tablet weight and hardness.
• Consistent dissolution across strengths.
• Moisture and temperature control.
• Stability-indicating analytical methods.
• Cross-contamination prevention.
• Reliable suppliers for specialized capsule shells or packaging.
• Validation of low-dose cleaning procedures.
• Demonstration of bioequivalence.

Softgel manufacturing adds liquid-fill encapsulation, shell compatibility, leakage control, and long-term stability. Oral solutions add microbial control, container compatibility, dosing accuracy, and preservative or aseptic-process decisions.

These barriers may produce stronger practical protection than a narrow patent. A competitor can legally design around a formulation but still face high development, validation, and scale-up costs.

How does levothyroxine compare with other narrow therapeutic index drugs?

Levothyroxine differs from many conventional generics because dose consistency and product switching receive substantial clinical attention. Warfarin and tacrolimus also have narrow therapeutic windows, but levothyroxine has a large chronic-use population and extensive multi-strength prescribing.

Attribute	Levothyroxine sodium	Typical broad-therapeutic-index generic
Dose range	Microgram strengths	Often milligram strengths
Switching sensitivity	Clinically important for some patients	Usually less prominent
Formulation opportunity	Softgel, oral solution, low-excipient tablet	Often centered on tablet cost
Bioequivalence sensitivity	High	Variable
Chronic use	Usually long term	Depends on therapy
Commercial differentiation	Delivery, tolerability, consistency, supply	Price and channel access

The strongest levothyroxine opportunity is not another undifferentiated tablet. It is a product that combines a credible delivery advantage with a clear patient segment and reliable reimbursement access.

What revenue exposure and launch scenarios exist?

Revenue exposure depends on the product's ability to command a premium over low-cost tablets. Three launch scenarios are commercially relevant.

Premium specialty formulation

A softgel or oral solution targets patients with absorption concerns, excipient sensitivities, dysphagia, or unstable thyroid control. The product can support higher gross margins but faces payer scrutiny and generic substitution.

Value-differentiated generic

A lactose-free, dye-free, sugar-free, or supply-reliable tablet competes at a modest premium or through preferred formulary placement. The key risks are rapid price erosion and limited pharmacist ability to distinguish products.

Institutional and pediatric platform

Unit-dose solutions or easy-to-administer products target hospitals, long-term care, pediatric practices, and specialty pharmacies. Volume may be lower, but packaging and dosing value can reduce direct price comparison.

Commercial diligence should monitor:

• Prescription volume by dosage form.
• Net price after rebates.
• Generic substitution rates.
• Reimbursement restrictions.
• Product availability by strength.
• Back-order frequency.
• Switching rates.
• Patient-support costs.
• Cost of goods for softgel shells and unit-dose packaging.

What is the best excipient strategy for a new levothyroxine product?

The strongest strategy is to select a defined patient problem first and then design the excipient system around it.

Target segment	Preferred formulation direction	Main proof point
Patients with excipient sensitivities	Low-excipient, lactose-free, dye-free tablet or softgel	Clear inactive-ingredient profile
Patients with dysphagia	Softgel or oral solution	Administration success and dose accuracy
Patients with absorption variability	Softgel or oral solution	Comparative pharmacokinetic or clinical evidence
Pediatric patients	Unit-dose oral solution	Palatability, dosing accuracy, stability
Long-term-care facilities	Unit-dose liquid or easy-to-administer capsule	Workflow and administration reliability
Cost-sensitive population	Robust tablet with simple excipients	Low manufacturing cost and supply resilience

The highest-value development path is a differentiated softgel or oral solution supported by a narrow patient segment, strong stability data, scalable manufacturing, and a defensible regulatory position. A conventional tablet can succeed, but usually through supply reliability, procurement access, or a specific excipient claim rather than broad patent exclusivity.

Key Takeaways

• Levothyroxine sodium has no meaningful new-molecule exclusivity remaining.
• Commercial differentiation is concentrated in softgels, oral solutions, unit-dose packaging, pediatric delivery, and low-excipient formulations.
• The narrow therapeutic index makes content uniformity, dissolution, potency, and bioequivalence central development risks.
• Tirosint and Tirosint-SOL illustrate the strongest formulation-led commercial models.
• Conventional tablet opportunities are more likely to depend on price, supply reliability, excipient exclusions, or channel strategy.
• Paragraph IV risk is product-specific and greatest for successful branded softgel or oral-solution products with listed patents.
• Manufacturing know-how can create practical barriers even when patent protection is narrow.
• A new entrant should avoid an undifferentiated tablet strategy unless it has a clear cost, supply, reimbursement, or excipient advantage.

FAQs

Can levothyroxine sodium be formulated without lactose?

Yes. Products can use calcium sulfate, mannitol, microcrystalline cellulose, or other fillers instead of lactose. The final product must meet potency, content-uniformity, dissolution, stability, and bioequivalence requirements.

Is a levothyroxine oral solution automatically better than a tablet?

No. An oral solution may improve administration for selected patients, but clinical value depends on dose accuracy, stability, absorption, tolerability, adherence, and reimbursement. The formulation must demonstrate a meaningful product advantage.

Which excipient creates the greatest levothyroxine formulation risk?

No single excipient determines risk. The greatest technical risk usually comes from the interaction of microgram-scale drug loading, blend uniformity, moisture control, lubricant level, dissolution behavior, and packaging.

Can a generic levothyroxine product use different excipients from the reference product?

Yes, provided the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, safety, and labeling. Different excipients can still affect dissolution, stability, tolerability, or absorption and must be evaluated appropriately.

Is compounded levothyroxine a direct commercial substitute for FDA-approved products?

No. Compounded products may provide customized strengths or dosage forms, but they do not have the same FDA approval, manufacturing controls, therapeutic-equivalence evaluation, or standardized interchangeability framework as approved commercial products.

References

1. DailyMed. (n.d.). Synthroid: Levothyroxine sodium tablet, prescribing information. U.S. National Library of Medicine.

2. DailyMed. (n.d.). Tirosint: Levothyroxine sodium capsule, prescribing information. U.S. National Library of Medicine.

3. DailyMed. (n.d.). Tirosint-SOL: Levothyroxine sodium solution, prescribing information. U.S. National Library of Medicine.

4. DailyMed. (n.d.). Euthyrox: Levothyroxine sodium tablet, prescribing information. U.S. National Library of Medicine.

5. DailyMed. (n.d.). Levothyroxine sodium tablets, prescribing information. U.S. National Library of Medicine.

6. U.S. Food and Drug Administration. (2017). Levothyroxine sodium products: Drug safety communication and administration information.

7. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development. Center for Drug Evaluation and Research.

8. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.